Biomea Fusion Inc

NASDAQ BMEA
$1.92 0.09 4.92%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 17.5 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
78.02M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
43.58M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
36.63M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-50.52 %

Upcoming events Biomea Fusion Inc

All events
No upcoming events scheduled

Stock chart Biomea Fusion Inc

Stock analysis Biomea Fusion Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.61 -1.33
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
2.72 1.16
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.35 -0.77
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.28 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-447.60 -48.88

Price change Biomea Fusion Inc per year

1.43$ 12.41$
Min Max

Summary analysis Biomea Fusion Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Biomea Fusion Inc

Revenue and net income Biomea Fusion Inc

All parameters

About company Biomea Fusion Inc

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Address:
900 Middlefield Road, Redwood City, CA, United States, 94063
Company name: Biomea Fusion Inc
Issuer ticker: BMEA
ISIN: US09077A1060
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2021-04-16
Sector: Healthcare
Industry: Biotechnology
Site: https://biomeafusion.com